Playing 1/5
  • Major Depressive Disorder

    YouTube 03:46
  • The power of the placebo effect - Emma Bryce

    YouTube 04:38
  • Bioavailability

    YouTube 03:43
  • Pharmacokinetics Part 2: Distribution, protein binding, equilibrium

    YouTube 03:53
  • 2-Minute Neuroscience: Glutamate

    YouTube 01:59

Basimglurant (INN) is a negative allosteric modulator of the mGlu5 receptor which is under development by Roche and Chugai Pharmaceutical for the treatment of treatment-resistant depression and fragile X syndrome. As of November 2016, it has undergone phase II clinical trials for both of these indications.

Discover in context

This site is not available in the landscape mode.
Please rotate your phone or install our app.